Still a Double- vtap mobile videos

1053

Marketocracy's Ken Kam thinks clinical results that battered innovative drug stock Elan are way overblown, and he still likes the stock.

2 months ago

MSN Video

Keep this video in the "Saved" list

Now, put vTap to work for you!

Let us keep you up to date with new videos related to:

Food and Drug Administration

Natalizumab

Clinical trial

Go to Feed to see what's new!

share

keep

Kam's Update on Elan

11624

Strategy Lab veteran Ken Kam has long favored drug company Elan, and now updates his forecast in response to the big recent drop in the share price.

3 months ago

MSN Video

Keep this video in the "Saved" list

Now, put vTap to work for you!

Let us keep you up to date with new videos related to:

Corporate law

Share price

Natalizumab

Go to Feed to see what's new!

share

keep

Double Dose of Drug Earnings

Pharma heavyweights Eli Lilly and Bristol Meyers Squibb report earnings, with CNBC's Mike Huckman

1m 52s |

4 months ago

CNBC Video Gallery - CNBC.com

Keep this video in the "Saved" list

Now, put vTap to work for you!

Let us keep you up to date with new videos related to:

CNBC

Pharmaceutical company

Bristol-Myers Squibb

Go to Feed to see what's new!

share

keep

Breaking News: ELN

Wyeth/Elan Alzheimer's drug results are out, with CNBC's Mike Huckman

4m 20s |

4 months ago

CNBC Video Gallery - CNBC.com

Keep this video in the "Saved" list

Now, put vTap to work for you!

Let us keep you up to date with new videos related to:

CNBC

Go to Feed to see what's new!

share

keep

Kam's 2008 Outlook

4883

Marketocracy founder Ken Kam gives his outlook for the second half of the year and names his portfolio's top-performing stock pick.

6 months ago

MSN Video

Keep this video in the "Saved" list

Now, put vTap to work for you!

Let us keep you up to date with new videos related to:

Health care

Go to Feed to see what's new!

share

keep